SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Investigating the landscape of US orphan product approvals
12 references·0 citing·31 second hop
Investigating the landscape of US orphan product approvals (2018)Investigating the landscape of US orphan …Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics (2017)Giving Drugs a Second Chance:…Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? (2017)Ethical imperatives of timely…Rare diseases and orphan drugs (2012)Rare diseases and orphan drugsRare diseases, orphan drugs and their regulation: questions and misconceptions (2010)Rare diseases, orphan drugs a…Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years (2010)Emergence of orphan drugs in …The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? (2009)The US Orphan Drug Act: Rare …Trends in the global funding and activity of cancer research (2008)Trends in the global funding …Incentives for orphan drug research and development in the United States (2008)Incentives for orphan drug re…Economics of New Oncology Drug Development (2007)Economics of New Oncology Dru…Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications (2006)Reimbursement for Cancer Trea…Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases (2006)Adopting Orphan Drugs — Two D…Two decades of orphan product development (2002)Two decades of orphan product…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Estimating the budget impact of orphan medicines in Europe: 2010 - 2020 (2011)Orphan drug development: an economically viable strategy for biopharma R&D (2012)Orphan drugs: the regulatory environment (2012)Why rare diseases are an important medical and social issue (2008)The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs (2015)Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (2017)The Two Cultures and the Scientific Revolution (1961)The genetical evolution of social behaviour. I (1964)The Evolution of Reciprocal Altruism (1971)A Current Global View of Environmental and Occupational Cancers (2011)Funding Data from Publication Acknowledgments: Coverage, Uses, and Limitations (2016)Radiation Therapy Research: A Global Analysis 2001-2015 (2018)A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)Market incentives and pharmaceutical innovation (2008)Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases (2013)Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases (2021)Cost of innovation in the pharmaceutical industry (1991)The price of innovation: new estimates of drug development costs (2003)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)The High Cost of Cancer Drugs and What We Can Do About It (2012)Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018)New uses for old drugs (2007)Lessons from 60 years of pharmaceutical innovation (2009)Diagnosing the decline in pharmaceutical R&D efficiency (2012)On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients (2020)Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers (2021)Drug repurposing: a systematic review on root causes, barriers and facilitators (2022)Policies and Incentives for Promoting Innovation in Antibiotic Research (2010)What Is Wrong with Orphan Drug Policies? (2012)Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives (2012)
this work references cited by second hop

References

  • 2007Economics of New Oncology Drug Development348 cited
  • 2017Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics281 cited
  • 2012Rare diseases and orphan drugs214 cited
  • 2010Rare diseases, orphan drugs and their regulation: questions and misconceptions182 cited
  • 2009The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?166 cited
  • 2006Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases162 cited
  • 2010Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years148 cited
  • 2002Two decades of orphan product development138 cited
  • 2008Incentives for orphan drug research and development in the United States138 cited
  • 2008Trends in the global funding and activity of cancer research114 cited
  • 2017Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?113 cited
  • 2006Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications81 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work